New horizons for cancer gene therapy

Cancer Gene Therapy

Volumn 21, Issue 1, 2014, Pages 1-

  Libutti, S K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

NANOMATERIAL;

BACTERIOPHAGE; CANCER GENE THERAPY; CELL THERAPY; EDITORIAL; GENE TARGETING; HUMAN; HYBRID; IMMUNOREGULATION; IMMUNOTHERAPY; KIDNEY CARCINOMA; MELANOMA; PRIORITY JOURNAL; TUMOR GENE;

CELL- AND TISSUE-BASED THERAPY; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84893658861     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.80     Document Type: Editorial

References (6)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Koldehoff M, Zakrzewski JL, Beelen DW, Elmaagacli AH. Additive antileukemia effects by GFI1B-and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells. Cancer Gene Ther 2013; 20: 421-427.
3. Zhao J, Jin J, Zhang X, Shi M, Dai J, Wu M et al. Transfection of Smac sensitizes tumor cells to etoposide-induced apoptosis and eradicates established human hepatoma in vivo. Cancer Gene Ther 2006; 13: 420-427.
4. Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013; 13: 525-541.
5. Yuan Z, Syrkin G, Adem A, Geha R, Pastoriza J, Vrikshajanani C et al. Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-a leads to synergistic antitumor activity. Cancer Gene Ther 2013; 20: 46-56.
6. Citrin D, Camphausen K, Wood BJ, Quezado M, Denobile J, Pingpank JF et al. A pilot feasibility study of TNFeradet biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer. Oncology 2010; 79: 382-388.